M&G Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

M&G Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9,106	Closed	-$519	–	573
2021 Q3	$519	Sell	9,106 -6,326	-41%	-$313K	﹤0.01%	673
2021 Q2	$679	Buy	+15,432	New	+$756K	﹤0.01%	658

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

M&G Investment Management's ENTA Position: Q4 2021 in Review

M&G Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2021, closing a stake of 9,106 shares — an estimated $519 sold.

M&G Investment Management first reported a position in ENTA in Q2 2021 and held it in 2 quarters. The position peaked at $679 in Q2 2021. 179 funds tracked by Wall St. Rank hold ENTA as of Q4 2021.

M&G Investment Management reported no remaining Enanta Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
M&G Investment Management sold 9,106 Enanta Pharmaceuticals shares in Q4 2021, an estimated $519.
M&G Investment Management first reported a position in Enanta Pharmaceuticals in Q2 2021 and held it in 2 quarters.
M&G Investment Management's Enanta Pharmaceuticals position peaked at $679 in Q2 2021.
179 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.